Bottom line
Medicare Part D has historically excluded anti-obesity medications under a statutory provision in the Social Security Act. That is changing. The Medicare GLP-1 Bridge program launches July 1, 2026, offering eligible Medicare beneficiaries access to certain GLP-1 medications for $50 per month through December 31, 2027. Meanwhile, the Treat and Reduce Obesity Act has been reintroduced in Congress but has not yet passed. If you have Medicare and want GLP-1 access for weight loss, the Bridge program is the most concrete near-term pathway.
The current Medicare exclusion: why weight-loss drugs are not covered
Since the inception of Medicare Part D in 2006, anti-obesity medications have been excluded from coverage. The statutory basis is section 1860D-2(e)(2) of the Social Security Act, which excludes drugs that may be excluded under Medicaid — including "agents when used for anorexia, weight loss, or weight gain."
CMS has interpreted this exclusion broadly: any medication used for weight loss or weight management is not a covered Part D drug, regardless of whether the patient has a clinical diagnosis of obesity. This means that even though the FDA has approved Wegovy and Zepbound specifically for chronic weight management in patients with obesity — a recognized chronic disease — Medicare Part D has not covered these medications when prescribed for that indication.
What is covered under current rules
Medicare Part D does cover GLP-1 medications when prescribed for FDA-approved indications other than weight loss:
| Medication | Covered indication | Not covered indication | |---|---|---| | Ozempic (semaglutide) | Type 2 diabetes | Weight management | | Mounjaro (tirzepatide) | Type 2 diabetes | Weight management | | Wegovy (semaglutide) | Not covered (obesity-only indication) | Weight management | | Zepbound (tirzepatide) | Not covered (obesity-only indication) | Weight management |
If you have type 2 diabetes and your prescriber prescribes Ozempic or Mounjaro for diabetes management, Medicare Part D will generally cover the medication. Weight loss that occurs as a side effect of diabetes treatment is not a barrier to coverage. However, Wegovy and Zepbound — which are FDA-approved only for weight management — are not covered under standard Part D.
The practical workaround many patients use
Because Ozempic and Mounjaro are covered for diabetes, some prescribers prescribe these medications for patients who have both obesity and type 2 diabetes (or prediabetes). The medication treats the diabetes indication, and weight loss occurs as a secondary benefit. This is a legitimate clinical approach when the patient genuinely has a diabetes diagnosis — it is not gaming the system.
However, patients who have obesity without diabetes or prediabetes do not have this option under current Part D rules.
The Medicare GLP-1 Bridge program: what launches July 1, 2026
The Medicare GLP-1 Bridge is a short-term demonstration program announced by CMS on December 23, 2025, and refined through subsequent guidance in early 2026. It represents the first time Medicare will provide access to GLP-1 medications specifically for weight management.
Key program details
Dates: July 1, 2026, through December 31, 2027
Cost to beneficiaries: $50 per month
Eligible medications: Foundayo (oral tirzepatide), Wegovy injection, Wegovy oral tablets, and Zepbound KwikPen — all when used to reduce excess body weight and maintain weight reduction
Who can participate: Medicare beneficiaries enrolled in a standalone prescription drug plan (PDP) or Medicare Advantage plan that offers prescription drug coverage (MA-PD plan) in calendar year 2026. Beneficiaries in Special Needs Plans (SNPs), employer or union group waiver plans (EGWPs), and the Limited Income Newly Eligible Transition (LI NET) program are also eligible.
Prior authorization: Required. CMS will use a single central processor to manage prior authorization, claims adjudication, and payment to pharmacies. Specific prior authorization criteria have not been fully detailed as of May 2026, but are expected to include BMI documentation and clinical assessment.
Administration: CMS will handle all program administration centrally, rather than delegating to individual Part D plan sponsors. This means the process should be uniform across all participating plans.
How the Bridge program works
1. Your prescriber determines that a GLP-1 medication is appropriate for weight management 2. Your prescriber submits a prior authorization request through the central CMS processor 3. If approved, you fill your prescription at a participating pharmacy 4. You pay $50 per month out of pocket 5. CMS pays the remaining cost directly to the pharmacy
What happened to the BALANCE Model
The BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model was originally announced alongside the Medicare GLP-1 Bridge as a longer-term framework for Medicare GLP-1 coverage starting in 2027. However, on April 21, 2026, CMS announced that it would not move forward with implementing the BALANCE Model in Medicare in 2027. Instead, CMS extended the Medicare GLP-1 Bridge through the end of 2027.
The future of Medicare GLP-1 coverage beyond December 2027 remains uncertain. It will depend on Congressional action (potentially the TREAT Act), future CMS rulemaking, or a new demonstration model.
The TREAT Act: Congressional efforts to change Medicare law
The Treat and Reduce Obesity Act is bipartisan legislation that would amend the Social Security Act to remove the statutory exclusion of anti-obesity medications from Medicare Part D coverage. The bill has been introduced in multiple Congressional sessions.
Legislative history
| Year | Bill | Status | |---|---|---| | 2021 | Treat and Reduce Obesity Act of 2021 | Introduced, did not advance | | 2023 | H.R.4818 / S. equivalent | Introduced, did not pass during 118th Congress | | 2024 | Amended version (House) | Limited coverage proposal; not voted on | | 2025 | S.1973 / H.R.4231 (119th Congress) | Reintroduced; pending committee action |
What the TREAT Act would do
If passed, the TREAT Act would:
- Remove anti-obesity medications from the list of excluded Part D drugs
- Allow Medicare Part D plans to cover FDA-approved anti-obesity medications for the treatment of obesity
- Apply standard Part D cost-sharing rules, including the Inflation Reduction Act's $2,000 annual out-of-pocket cap
Budget and political considerations
The Congressional Budget Office has estimated that covering anti-obesity medications under Part D would cost the federal government tens of billions of dollars over 10 years, depending on uptake assumptions. This cost has been the primary obstacle to passage in prior Congressional sessions.
The April 2025 decision by the Trump Administration not to broaden Medicare coverage of anti-obesity drugs through rulemaking returned the issue to Congress. As of May 2026, the TREAT Act has bipartisan support but faces the same budget hurdle that has stalled it in previous sessions.
Medicare Advantage plans: a separate path
Medicare Advantage (MA) plans — the private-plan alternative to traditional Medicare — have more flexibility in benefit design than traditional Part D. Some MA plans have begun offering supplemental benefits that include weight-management programs, nutritional counseling, and in some cases, limited GLP-1 coverage as a supplemental benefit.
How MA coverage differs
- MA plans can offer benefits beyond what traditional Medicare covers, funded through plan rebates
- Some MA-PD plans have added GLP-1 coverage for weight management as a supplemental benefit, with varying cost-sharing
- The Medicare GLP-1 Bridge program applies to MA-PD plans, so eligible MA enrollees will have access starting July 1, 2026
- MA plans that already offered supplemental GLP-1 coverage may integrate with the Bridge program for more favorable cost-sharing
Finding MA plans with GLP-1 coverage
During Medicare Open Enrollment (October 15 through December 7), you can compare MA plans in your area at medicare.gov. Look for plans that include weight-management or anti-obesity medication benefits in their supplemental coverage. You can also call 1-800-MEDICARE for assistance comparing plans.
How to get GLP-1 coverage through Medicare today
If you have type 2 diabetes
Your clearest path is through the diabetes indication. Ozempic and Mounjaro are covered under standard Part D for type 2 diabetes. Work with your prescriber to ensure proper diagnosis coding (ICD-10 E11.x series) and documentation.
Cost under Part D varies by plan but is subject to the Inflation Reduction Act's $2,000 annual out-of-pocket cap, which took effect in 2025. Once you hit $2,000 in total Part D out-of-pocket spending for the year, you pay nothing for covered drugs for the rest of the year.
If you do not have diabetes but have obesity
Starting July 1, 2026: Enroll in the Medicare GLP-1 Bridge program. Watch cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge for enrollment details and prior authorization requirements as they are finalized.
Before July 1, 2026: Your options are limited under Medicare. Consider:
- Manufacturer patient assistance programs: Novo Nordisk and Eli Lilly offer patient assistance programs for Medicare beneficiaries with limited income (generally under 300 percent of the federal poverty level)
- Cash-pay options: Novo Nordisk's self-pay program offers Wegovy at $349 per month (or $149 for the oral tablet). This is outside of Medicare and paid entirely out of pocket.
- Medicare Advantage supplemental benefits: Check whether your MA plan offers any weight-management medication coverage as a supplemental benefit
Projected timeline for full Medicare GLP-1 coverage
| Timeframe | Expected development | |---|---| | July 1, 2026 | Medicare GLP-1 Bridge launches ($50/month) | | Late 2026 | TREAT Act may see committee action in 119th Congress | | December 31, 2027 | Medicare GLP-1 Bridge currently scheduled to end | | 2027–2028 | CMS may propose new demonstration model or permanent coverage rule | | 2032 | U.S. semaglutide patents expire, opening door to generic competition |
The trajectory is toward broader coverage, but the timeline is uncertain. Congressional action through the TREAT Act would provide the most durable solution, but budget considerations continue to slow progress. In the meantime, the Medicare GLP-1 Bridge provides a meaningful — if temporary — pathway.
Consult your healthcare provider about whether a GLP-1 medication is appropriate for you, and contact 1-800-MEDICARE or visit medicare.gov for the latest information on the GLP-1 Bridge program.
[guide:employer-health-plan-glp1-coverage] · [guide:fsa-hsa-for-glp1-medications] · [guide:glp1-manufacturer-savings-programs] · [program:medicare]